Kymera Therapeutics, Inc. KYMR
111.95
(3.86)
(3.33%)
as of 25 Sep
- Market cap
- $9.7B
- P/E
- 0.0×
Follow KYMR
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
107.22 | 157.81 | 167.66 | 112.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(208.23) | (91.44) | (98.49) | (182.26) | |
P/B ratio |
7.46 | 5.28 | 4.16 | 5.22 | |
Price to Tangible BV |
7.46 | 5.28 | 4.16 | 5.22 | |
EV/Sales |
100.65 | 145.19 | 146.07 | 101.46 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(44.63) | (30.81) | (24.59) | (19.47) | |
EV/FCF |
(44.41) | (30.63) | (24.44) | (19.28) | |
Quick Ratio |
9.97 | 10.39 | 10.19 | 7.07 | |
Current Ratio |
10.34 | 10.81 | 10.47 | 7.38 | |
Net Debt/EBITDA |
9.09 | 7.66 | 8.65 | 5.44 | |
Debt/Assets |
0.05% | 0.07% | 0.08% | 0.16% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.08 | 0.04 | 0.03 | 0.04 | |
Operating CF/Net income |
0.88 | 1.28 | 0.77 | 0.33 | |
Capex/Depreciation |
1.59 | 0.61 | 8.15 | 4.64 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
183.82% | 285.65% | 2,919.92% | 2,680.68% | |
Selling, General and Administrative Expense of Revenue |
32.50% | 59.24% | 589.86% | 627.21% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
29.14% | 46.58% | 503.41% | 571.71% | |
Graham Net Nets |
0.05 | 0.07 | 0.11 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.83%) | (4.29%) | (4.73%) | (6.34%) | |
Free Cash Flow Yield |
(2.11%) | (3.00%) | (3.56%) | (4.66%) | |
Revenue per Share |
0.66 | 0.35 | 0.03 | 0.03 | |
Operating CF per Share |
(0.55) | (0.91) | (0.79) | (0.31) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.56) | (0.92) | (0.79) | (0.31) | |
Cash per Share |
7.04 | 6.67 | 10.04 | 5.79 | |
Shareholders Equity per Share |
15.37 | 15.79 | 18.70 | 10.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.37 | 15.79 | 18.70 | 10.84 | |
Free Cash Flow |
(54.54) | (89.27) | (66.85) | (27.29) | |
Working Capital |
665.94 | 614.79 | 788.00 | 456.72 | |
Capital Expenditures |
(0.47) | (0.43) | (0.11) | (0.18) | |
Net Current Asset Value |
601.08 | 548.05 | 708.07 | 372.51 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.04 | 0.07 | |
Net Profit Margin |
(94.17%) | (201.47%) | (3,029.64%) | (2,973.05%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.06 | — | — | — | |
Average Payables |
7.35 | 11.55 | 5.00 | 6.00 | |
Average Assets |
1,388.26 | 1,293.66 | 1,360.42 | 1,068.44 | |
Average Common Equity |
1,240.37 | 1,162.94 | 1,207.64 | 919.59 |
Columns are period end dates